sever
combin
immunodefici
scid
mous
adapt
immun
lack
matur
b
cell
peripher
blood
lymphoid
organ
use
extens
biomed
research
valuabl
translat
model
xenoengraft
human
tissu
cell
review
focus
engraft
human
peripher
blood
cell
tissu
scid
mice
well
newli
establish
permiss
scid
mice
defici
receptor
human
immun
respons
could
elicit
assess
human
scid
mice
upon
vaccin
sensit
allogen
tissu
translat
model
propos
attain
preclin
data
test
human
vaccin
keyword
preclin
model
sever
combin
immunodefici
mice
vaccin
develop
sever
combin
immunodefici
scid
mous
adapt
immun
lack
matur
b
cell
peripher
blood
lymphoid
organ
discov
approxim
year
ago
laboratori
melvin
bosma
fox
chase
cancer
center
pa
usa
spontan
mutat
note
coloni
balbc
mice
line
investig
studi
allotyp
mous
immunoglobulin
mice
found
minim
mous
immunoglobulin
upon
investig
lack
matur
b
cell
precursor
b
cell
fail
differenti
function
immun
cell
point
mutat
later
identifi
affect
catalyt
subunit
mous
dnadepend
protein
kinas
result
sever
impair
recombin
tand
bcell
receptor
mice
howev
viabl
surviv
quit
well
pathogenfre
environ
mainli
util
innat
immun
natur
killer
nk
cell
myeloid
cell
monocyt
cell
immun
defens
correspond
lupu
research
floor
view
limit
abil
mount
immun
respons
foreign
tissu
immunologist
quickli
realiz
advantag
scid
mous
accept
allograft
xenograft
inde
mosier
et
al
mccune
et
al
publish
find
engraft
human
peripher
blood
mononuclear
cell
pbmc
human
fetal
thymusliv
mice
terminolog
huscidpbl
scidhu
thyliv
use
respect
distinguish
two
experiment
system
develop
two
model
xenograft
concur
discoveri
hiv
propag
human
immun
cell
system
success
use
test
therapeut
hiv
improv
understand
pathophysiolog
viru
howev
found
origin
mice
could
leaki
mice
get
older
spontan
repair
defect
could
often
circul
immunoglobulin
shultz
et
al
later
bred
scid
mutat
onto
nonobes
diabet
nod
mous
creat
nodscid
mous
reduc
leaki
lower
level
nk
cell
defect
complement
system
develop
modif
nodscid
mice
detail
recent
review
shultz
et
al
signific
advanc
within
human
mous
model
creation
scid
mous
disrupt
receptor
chain
c
knockout
ko
common
cytokin
receptor
four
independ
laboratori
creat
studi
four
separ
line
mice
use
engraft
human
hematopoiet
cell
tissu
two
mous
line
balbc
mous
recombin
activ
gene
delet
thu
similar
scid
phenotyp
lack
matur
b
cell
origin
balbc
use
spit
laboratori
mous
gener
bern
p
krimpenfort
netherland
cancer
institut
amsterdam
netherland
spit
h
per
comm
mous
use
manz
studi
came
ito
central
institut
experiment
anim
ciea
kawasaki
japan
two
scid
line
nodscid
mice
origin
ito
ciea
l
shultz
jackson
laboratori
bar
harbor
usa
design
nog
nsg
respect
nog
nsg
mice
dko
ito
mice
mice
permiss
host
xenograft
particular
human
stem
cell
due
part
lack
nk
cell
whose
differenti
depend
cytokin
subsequ
origin
public
mani
laboratori
use
variou
strategi
achiev
engraft
human
stem
cell
succeed
effect
differenti
develop
matur
b
cell
monocyt
nk
cell
human
granulocyt
erythrocyt
howev
well
popul
human
mice
data
extens
describ
sever
review
number
summar
tabl
howev
except
use
human
fetal
thymu
engraft
emerg
human
cell
educ
mous
thymu
epithelium
appear
exhibit
mous
tcell
restrict
human
tcell
receptor
rearrang
viral
epitop
recogn
immun
cell
context
mous
mhc
molecul
rather
human
epsteinbarr
viru
ebv
influenza
system
thu
hypothes
provid
human
mhc
hla
class
ii
transgen
nog
nsg
dko
mice
would
allow
engraft
human
pret
cell
educ
select
thymu
epithelium
bear
human
mhc
element
class
ii
transgen
develop
humanlik
tcell
repertoir
respons
accordingli
investig
current
establish
scid
nsg
mice
transgen
hla
class
gene
allel
nodscidhlaa
mice
well
transgen
hla
class
ii
mice
review
shall
focu
variou
protocol
engraft
human
pbmc
umbil
cord
blood
mononuclear
cell
cbmc
scid
scid
mice
use
vaccin
develop
simplic
scid
mice
includ
nodscid
mice
without
nog
ito
mice
nsg
l
shultz
mice
use
respect
mice
applic
advantag
engraft
pbmc
cbmc
eas
obtain
cell
engraft
scid
mice
human
mous
model
provid
uniqu
vivo
system
enabl
studi
effect
antigen
stimul
vaccin
support
increas
public
describ
applic
shortterm
engraft
pbmc
cbmc
matur
cell
test
vaccin
therapeut
scid
mice
earlier
studi
mosier
et
al
mice
engraft
human
pbmc
consist
lymphocyt
monocyt
granulocyt
preclin
model
test
therapeut
hiv
viru
establish
million
pbmc
per
mous
administ
intra
periton
requir
high
inoculum
pbmc
part
due
presenc
nk
cell
lyse
inhibit
engraft
human
pbmc
use
nodscid
mice
lower
nk
activ
margin
improv
engraft
deplet
nk
activ
antink
antibodi
antibodi
improv
engraft
howev
syndrom
graftversushost
diseas
gvhd
often
occur
human
mous
model
engraft
anim
lost
weight
eventu
die
within
month
human
scid
mice
contribut
immens
biomed
research
despit
engraft
human
cell
within
spleen
blood
popul
tabl
list
studi
pbmc
cell
engraft
scid
mice
monitor
studi
infecti
diseas
autoimmun
diseas
system
lupu
erythematosi
lupu
skingraft
reject
adopt
tcell
immunotherapi
recent
mice
observ
give
superior
engraft
pbmc
king
et
al
present
data
detail
kinet
engraft
human
pbmc
nsg
mice
week
postengraft
compar
engraft
pbmc
nod
scid
versu
nsg
mice
clearli
demonstr
better
engraft
pbmc
nsg
mice
furthermor
million
cell
intraven
intraperiton
requir
achiev
engraft
cell
blood
spleen
king
et
al
also
test
immun
respons
engraft
pbmc
diabet
model
implant
human
islet
cell
spleen
chemic
induc
diabet
nsg
mous
upon
engraft
allogen
pbmc
exogen
human
islet
cell
destroy
result
subsequ
diabet
thu
studi
demonstr
pbmc
mice
mount
allogen
respons
human
islet
cell
studi
test
put
vaccin
okada
et
al
transfus
approxim
million
pbmc
intraperiton
nog
mice
immun
human
mice
cdna
construct
antigen
protein
sever
acut
respiratori
corona
viru
three
immun
could
demonstr
antibodi
respons
well
modest
cytotox
tcell
respons
specif
viru
studi
show
pbmcengraft
nsg
nog
mice
could
mount
specif
immun
respons
base
encourag
result
naiv
human
cell
develop
stem
cell
variou
mice
sensit
ebv
immun
human
mice
human
cytomegaloviru
cmv
antigenpres
cell
rational
investig
found
previou
margin
success
obtain
vitro
cmv
antigenspecif
cell
pbmc
cmvseroneg
individu
use
mice
base
assumpt
antigenpres
cell
mice
facilit
improv
immun
respons
thu
infus
pbmc
deriv
seri
healthi
seroneg
hla
nonhla
volunt
donor
nonirradi
mice
pbmc
intraperiton
pbmc
via
intraven
rout
total
million
cell
per
mous
subsequ
day
immun
mice
subcutan
inocul
irradi
hla
artifici
antigenpres
cell
aapc
transduc
express
immunogen
aapc
mous
nih
fibroblast
engin
express
human
class
hla
allel
process
effici
present
viral
epitop
express
hla
allel
elicit
function
virusspecif
human
tcell
respons
previous
demonstr
papanicola
et
al
aapc
express
human
costimulatori
molecul
well
b
singl
hla
class
heavychain
molecul
hlaa
cell
thu
use
surrog
vaccin
day
follow
twiceweekli
immun
spleen
cell
analyz
level
human
tcell
engraft
cultur
stimul
vitro
cell
respons
time
spleen
cell
human
mononuclear
cell
among
cell
cell
cell
harvest
splenic
cell
subsequ
expand
vitro
addit
day
presenc
irradi
hlamatch
cell
test
tcell
respons
includ
quantif
cell
bind
peptid
tetram
product
human
cell
sensit
specif
cmv
peptid
found
approxim
cell
epitopehla
tetramerposit
cell
approxim
cell
also
gener
specif
respons
stimul
peptideload
autolog
ebvtransform
b
cell
therefor
studi
suggest
vivo
sensit
human
nsg
mous
may
inde
elicit
primari
tcell
respons
naiv
popul
cmvseroneg
individu
tabl
show
summari
immun
function
spleen
cell
human
mice
immun
cell
interestingli
donor
also
respond
immun
cell
tabl
although
peptid
tetram
test
antigenspecif
cell
result
suggest
antigen
like
process
autolog
antigenpres
cell
mice
howev
eventu
lost
approxim
weight
week
becam
anem
end
studi
mice
studi
die
mice
gener
show
engraft
cell
exhibit
typic
gvhd
skin
lesion
enter
perhap
consist
observ
littl
engraft
human
cell
mesenter
node
peyer
patch
human
mice
su
l
per
comm
probabl
due
mutat
also
intraven
transfus
million
mice
observ
similar
engraft
pbmc
use
furthermor
also
elicit
immun
respons
restrict
allel
cmv
system
data
shown
present
preliminari
data
suggest
immun
respons
pbmc
mice
appear
better
compar
engraft
donor
nsg
mice
therefor
result
substanti
content
mice
could
respond
novel
antigen
repres
uniqu
preclin
translat
model
vaccin
develop
due
undesir
outcom
gvhd
engraft
pbmc
cbmc
use
engraft
nodscid
mice
expect
naiv
tcell
cbmc
mount
gvhd
readili
matur
cell
adult
pbmc
inde
fewer
symptom
weight
loss
anemia
relat
gvhd
although
engraft
cbmc
result
predominantli
b
cell
bone
morrow
littl
tcell
engraft
observ
altern
strategi
improv
engraft
human
cell
camacho
et
al
develop
nodscid
mous
hla
class
transgen
transgen
locat
chromosom
character
immunobiolog
innat
immun
nk
activ
lp
respons
antigen
present
found
similar
nodscid
mice
found
enhanc
engraft
human
cell
transgen
mice
compar
nodscid
mice
whether
donor
engraft
human
cbmc
result
slight
chang
architecturestructur
spleen
defin
germin
center
normal
spleen
chimer
mice
immun
adenoviru
cancer
vaccin
human
carcinoembryon
antigen
cea
engraft
human
cell
respond
cancer
vaccin
produc
intracellular
interferon
spleen
cell
immun
chimer
mice
cultur
vitro
cea
peptid
therefor
engraft
cbmc
respond
cea
vaccin
human
mice
present
breed
transgen
onto
nsg
background
render
mice
amend
engraft
human
hematopoiet
cell
elabor
earlier
sever
combin
immunodefici
mice
use
extens
preclin
model
tumor
engraft
understand
pathophysiolog
tumor
test
therapeut
agent
adopt
tcell
therapi
tumor
cell
introduc
mous
either
subcutan
intraven
intraparenter
administr
titer
tumor
stem
cell
demonstr
numer
studi
past
decad
summar
tabl
preclin
model
adopt
tcell
therapi
engraft
tumor
cell
could
label
transduct
bioluminesc
luciferin
imag
monitor
lytic
effect
tumorspecif
cell
cell
tumor
cell
label
differenti
probe
dye
number
cell
requir
treat
leukemia
tumor
cell
could
approxim
similarli
traffick
pattern
cell
could
assess
order
explor
mechan
home
adopt
transfer
cell
tumor
site
establish
cell
line
could
readili
engraft
scid
mice
engraft
primari
tumor
challeng
number
primari
leukemia
cell
could
propag
either
irradi
nonirradi
scid
mice
furthermor
success
secondari
transfer
bone
marrow
contain
leukemia
cell
anoth
scid
recipi
confirm
leukemia
stem
cell
establish
mice
regard
success
implant
leukemia
cell
nodscid
mice
yan
et
al
report
correl
aggress
leukemia
poor
outcom
patient
kong
et
al
also
use
nsg
mice
propag
primari
leukemia
cell
recapitul
leukemogenesi
patient
recent
studi
bankert
group
describ
use
nsg
mice
engraft
primari
human
lung
tumor
studi
tumorinfiltr
cell
identifi
tumorderiv
memori
effector
cell
anerg
could
activ
therefor
primari
human
cancer
cell
readili
engraft
scid
mice
particular
mice
studi
success
engraft
normal
human
skin
prostat
gland
pancreat
islet
scid
mice
tabl
pober
group
extens
studi
engraft
human
skin
mice
late
mice
order
explor
mechan
reject
role
endotheli
cell
xenotranspl
recent
moffat
group
engraft
nodscid
mice
human
fetal
skin
follow
infect
varicella
zoster
order
studi
diseas
process
viru
nodscid
mice
taylor
et
al
abl
grow
human
stem
cell
human
prostat
tissu
provid
microenviron
rat
prostat
tissu
mesenchym
cell
engraft
kidney
capsul
nsg
mice
use
recent
studi
human
diabet
model
islet
transplant
host
later
engraft
human
allogen
pbmc
becam
sensit
pancreat
islet
result
reject
islet
cell
describ
earlier
therefor
engraft
human
tissu
tumor
appropri
chosen
use
monitor
immun
respons
vaccin
human
mous
figur
accordingli
adult
pbmc
cbmc
millionmous
could
inject
either
intraven
via
combin
intraven
intraperiton
administr
million
rout
inject
recipi
could
includ
variou
nog
nsg
dko
scid
mice
without
hla
transgen
day
postinfus
human
cell
human
mice
could
immun
twoto
threetim
vaccin
interest
total
day
follow
second
third
immun
sensit
mice
could
challeng
specif
vaccin
antigen
form
tumor
cell
tissu
express
put
antigen
match
hla
haplotyp
donor
pbmc
cbmc
ideal
use
autolog
tumor
tissu
pbmccbmc
donor
would
best
strategi
avoid
allogen
rejectionreact
test
immun
respons
ex
vivo
immun
function
assay
could
also
assess
measur
product
vitro
antigen
stimul
commonli
perform
vaccin
evalu
experiment
protocol
would
mimic
immun
state
immun
human
mous
obliter
virusinfect
skin
tissu
reject
allogen
skin
graft
tumor
antigenspecif
manner
furthermor
concomit
express
human
hla
moleculestransgen
exampl
cbmcor
pbmcengraft
scid
mice
offer
opportun
test
put
toxic
immun
respons
cell
mous
tissu
mice
nodscid
balbc
background
except
use
model
engraft
human
cell
pbmc
cbmc
vaccin
develop
publish
data
support
content
engraft
pbmc
cbmc
mice
along
target
tissu
vaccin
present
uniqu
humanlik
entiti
caution
avoid
allogen
reactiv
pbmc
cbmc
toward
mhc
antigen
tissu
use
autolog
partial
match
mhcexpress
tissu
system
constitut
exquisit
approach
test
efficaci
human
vaccin
scid
mice
provid
valuabl
model
studi
human
immun
hematopoiesi
diseas
process
mice
current
permiss
host
engraft
human
cell
tissu
explor
pathophysiolog
effect
therapeut
vaccin
develop
infecti
diseas
cancer
advent
stem
cell
research
mani
organ
tissu
differenti
transplant
expect
promot
applic
uniqu
translat
model
direct
research
area
next
year
predict
includ
use
transgen
hla
class
class
ii
nog
nsg
mice
mice
signific
potenti
establish
refin
clinic
relev
human
model
humanlik
mhc
impact
studi
transplant
stem
cellderiv
tissu
well
studi
immun
respons
infecti
agent
cancer
present
mhc
tissu
transgen
mice
could
valuabl
model
assess
toxic
cellular
biolog
therapi
differ
mhcexpress
organ
system
improv
engraft
subset
hematopoiet
cell
myeloid
erythroid
compart
supplement
growth
factor
specif
cell
cell
type
current
well
repres
human
mice
enabl
develop
model
system
studi
diseas
aris
cell
compart
abil
immun
cell
engraft
mice
use
pbmc
cell
respond
antigen
challeng
human
mice
use
valid
system
translat
preclin
model
evalu
test
efficaci
vaccin
therapeut
sever
combin
immunodefici
scid
mice
disrupt
permiss
host
engraft
human
cell
tissu
human
stem
cell
could
differenti
mice
could
reconstitut
b
cell
natur
killer
cell
monocyt
compart
human
mice
human
scid
mice
use
studi
pathophysiolog
infecti
agent
hiv
ebv
therapeut
scid
mice
engraft
peripher
blood
mononuclear
cell
could
sensit
allogen
skin
graft
pancreat
islet
viral
vaccin
scid
mice
could
engraft
normal
human
tissu
skin
pancreat
islet
primari
tumor
cell
cell
line
human
nog
nsg
mice
engraft
peripher
blood
mononuclear
cell
could
immun
vaccin
assess
specif
immun
respons
infecti
agent
tumor
cell
constitut
preclin
small
anim
translat
model
immun
respons
human
mice
immun
cell
mice
engraft
three
differ
normal
donor
genotyp
neg
detect
cmv
antibodi
n
control
mice
per
donor
without
immun
n
mice
per
donor
immun
day
postinfus
human
pbmc
mice
immun
irradi
cell
day
postimmun
spleen
cell
analyz
human
cell
subset
cell
stimul
vitro
spleen
two
mice
pool
cultur
hlamatch
irradi
cell
day
cell
quantifi
cell
bind
tetram
pool
cultur
peptid
tetram
avail
present
studi
sampl
pool
cultur
test
product
incub
cmv
specif
peptid
present
autolog
pbmcor
ebvtransform
b
cell
neg
control
includ
nonspecif
tetram
peptid
valu
less
percentag
tetramerposit
cell
well
cell
similar
observ
cmvposit
donor
cultur
condit
n
aapc
artifici
antigenpres
cell
cmv
cytomegaloviru
ebv
epsteinbarr
viru
nd
detect
nsg
jackson
laboratori
mice
pbmc
peripher
blood
mononuclear
cell
